Combined Surgery, Radiation, and PCV Chemotherapy for Astrocytomas Compared to Oligodendrogliomas and Oligoastrocytomas WHO Grade III

[1]  M. Brada.  Pathology and Genetics of Tumours of the Nervous System , 2001, British Journal of Cancer.

[2]  J. Dichgans,et al.  A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors , 2000, Journal of Neurology.

[3]  M. Prados,et al.  Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  B. Jeremic,et al.  Combined Treatment Modality for Anaplastic Oligodendroglioma: A Phase II Study , 1999, Journal of Neuro-Oncology.

[5]  J. Gockerman,et al.  Acute leukemia following treatment of malignant glioma , 1998, Journal of Neuro-Oncology.

[6]  A. Twijnstra,et al.  Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy , 1998, Neurology.

[7]  J. Heimans,et al.  Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma , 1998, Journal of Neuro-Oncology.

[8]  J. Muscat,et al.  Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients. , 1998, Anticancer research.

[9]  J. Slattery,et al.  Chemotherapy response criteria in malignant glioma , 1997, Neurology.

[10]  D. Louis,et al.  Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. , 1996, Journal of neurosurgery.

[11]  S. Soong,et al.  The prognostic impact of prior low grade histology in patients with anaplastic gliomas , 1996, Neurology.

[12]  T. Cascino,et al.  Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Graham.  Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.

[14]  H. Fine,et al.  Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.

[15]  J. Bruner,et al.  The treatment of anaplastic oligodendrogliomas and mixed gliomas. , 1993, Neurosurgery.

[16]  David W. Smith,et al.  The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. , 1992, Journal of neurosurgery.

[17]  B. Scheithauer,et al.  Oligodendrogliomas: the Mayo Clinic experience. , 1992, Journal of neurosurgery.

[18]  J. Nazzaro,et al.  The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. , 1990, Journal of neurosurgery.

[19]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  P. Gutin,et al.  Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. , 1990, International journal of radiation oncology, biology, physics.

[21]  J. Cairncross,et al.  Successful chemotherapy for recurrent malignant oligodendroglioma , 1988, Annals of neurology.

[22]  V. Armbrustmacher,et al.  A clinicopathological study of 323 patients with oligodendrogliomas , 1986, Annals of neurology.

[23]  Webster K. Cavenee,et al.  Pathology and genetics of tumours of the nervous system. , 2000 .

[24]  W. Dupont,et al.  Power and sample size calculations. A review and computer program. , 1990, Controlled clinical trials.

[25]  Shapiro Wr,et al.  Chemotherapy of malignant glioma with CCNU alone and CCNU combined with vincristine sulfate and procarbazine hydrochloride. , 1976 .